Sanofi News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

10.02.22	Regeneron, Sanofi: FDA Accepts Dupixent Priority Review In Children With Atopic Dermatitis (RTTNews)
10.02.22	FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (GlobeNewswire)
09.02.22	Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD (GlobeNewswire)
05.02.22	Sanofi : FDA Approves Enjaymo, First Treatment For Use In Patients With Cold Agglutinin Disease (RTTNews)
04.02.22	FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease (GlobeNewswire)
04.02.22	Sanofi Q4 Results Rise; Sees Growth In FY22 Business EPS (RTTNews)
04.02.22	Sanofi Q4 Profit Rises; Sees 2022 Business EPS Growth To Be Low Double-digit At CER (RTTNews)
04.02.22	Sanofi Unveils New Corporate Brand And Logo (RTTNews)
03.02.22	Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity (GlobeNewswire)
31.01.22	Sanofi: CHMP Recommends Approval Of Dupixent For Children With Severe Asthma With Type2 Inflammation (RTTNews)
31.01.22	CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation (GlobeNewswire)
19.01.22	REGN : FDA Accepts For Review Libtayo-Chemotherapy Combination For Advanced Lung Cancer Treatment (RTTNews)
19.01.22	Sanofi Says Second Phase 3 Dupixent Trial Confirms Improvements For Patients With Prurigo Nodularis (RTTNews)
19.01.22	Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis (GlobeNewswire)
12.01.22	ABL Bio Enters Into Deal With Sanofi To Advance ABL301 For Parkinson's Disease Treatment (RTTNews)
07.01.22	Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines (GlobeNewswire)
06.01.22	Sangamo Says Sanofi To Transition Sickle Cell Disease Program Back To Sangamo - Quick Facts (RTTNews)
04.01.22	Availability of the Q4 2021 Memorandum for modelling purposes (GlobeNewswire)
30.12.21	Viatris Wins Court Decisions On Sanofi Appeals Of Lantus Patent Invalidations (RTTNews)
21.12.21	Sanofi To Buy Amunix For An Upfront Payment Of $1 Bln - Quick Facts (RTTNews)
16.12.21	Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi (GlobeNewswire)
16.12.21	Innate : First Patient Dosed In IPH6101/SAR443579 Phase 1/2 Trial In Various Blood Cancers (RTTNews)
15.12.21	Sanofi & GSK Report Positive Preliminary Booster Data For COVID-19 Vaccine Candidate (RTTNews)
15.12.21	Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation (GlobeNewswire)
14.12.21	Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessio (GlobeNewswire)
13.12.21	Regeneron : Phase 3 Results Show Dupixen Improved Skin Clearance In Children With Atopic Dermatitis (RTTNews)
13.12.21	Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session (GlobeNewswire)
09.12.21	Sanofi: Results Reinforce Safety Profile Of Dupixent In Children With Moderate-to-severe Asthma (RTTNews)
08.12.21	New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma (GlobeNewswire)
01.12.21	Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates (GlobeNewswire)
01.12.21	Sanofi To Buy Austrian Biotech Firm Origimm Biotechnology - Quick Facts (RTTNews)
01.12.21	Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy (GlobeNewswire)
30.11.21	Sanofi Raises Paid Parental Leave To 14 Weeks To Ensure Workplace Equality - Quick Facts (RTTNews)
22.11.21	Baidu, Sanofi Ink License Deal To Integrate Baidu's Design Into Sanofi's Product Design Pipeline (RTTNews)
18.11.21	Sanofi Invests $180 Mln Equity In AI Startup Owkin To Develop Oncology Pipeline (RTTNews)
18.11.21	Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline (GlobeNewswire)
09.11.21	Sanofi completes acquisition of Kadmon (GlobeNewswire)
29.10.21	Sanofi Says Health Canada OKs Libtayo For Locally Advanced Basal Cell Carcinoma - Quick Facts (RTTNews)
28.10.21	Sanofi Q3 Profit Increases; Lifts FY Business EPS Growth View - Quick Facts (RTTNews)
25.10.21	Regeneron, Sanofi Report Positive Data From Second Phase 3 Trial Of Dupixent In EoE Patients (RTTNews)
25.10.21	Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease (GlobeNewswire)
22.10.21	Regeneron : Dupixent Reduces Itch And Skin Lesions In Phase 3 Trial For Prurigo Nodularis (RTTNews)
22.10.21	Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease (GlobeNewswire)
20.10.21	FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma (GlobeNewswire)
13.10.21	New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 (GlobeNewswire)
30.09.21	Sanofi's Amlitelimab Shows Improvements In Symptoms Of Moderate-to-severe Atopic Dermatitis (RTTNews)
30.09.21	New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis (GlobeNewswire)
28.09.21	Sanofi Reports Positive Phase 1/2 Study Interim Data For First MRNA-based COVID-19 Vaccine Candidate (RTTNews)
28.09.21	Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate (GlobeNewswire)
24.09.21	Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
17:58		Handel in Europa: STOXX 50 schliesst im Minus
17:58		Schwacher Handel: SMI schliesst mit Verlusten
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		SPI-Handel aktuell: SPI zum Handelsende leichter
17:58		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
16:01		NASDAQ-Handel NASDAQ 100 schwächelt zum Start des Freitagshandels